Ad is loading...
AXDX
Price
$1.85
Change
-$0.02 (-1.07%)
Updated
Nov 15 closing price
HBIO
Price
$2.14
Change
-$0.15 (-6.55%)
Updated
Nov 15 closing price
108 days until earnings call
Ad is loading...

AXDX vs HBIO

Header iconAXDX vs HBIO Comparison
Open Charts AXDX vs HBIOBanner chart's image
Accelerate Diagnostics
Price$1.85
Change-$0.02 (-1.07%)
Volume$30.76K
CapitalizationN/A
Harvard Bioscience
Price$2.14
Change-$0.15 (-6.55%)
Volume$338.48K
CapitalizationN/A
AXDX vs HBIO Comparison Chart
Loading...
AXDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AXDX vs. HBIO commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXDX is a StrongSell and HBIO is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (AXDX: $1.85 vs. HBIO: $2.14)
Brand notoriety: AXDX and HBIO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: AXDX: 49% vs. HBIO: 257%
Market capitalization -- AXDX: $19.27M vs. HBIO: $184.01M
AXDX [@Medical Specialties] is valued at $19.27M. HBIO’s [@Medical Specialties] market capitalization is $184.01M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXDX’s FA Score shows that 1 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).

  • AXDX’s FA Score: 1 green, 4 red.
  • HBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, AXDX is a better buy in the long-term than HBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXDX’s TA Score shows that 2 TA indicator(s) are bullish while HBIO’s TA Score has 2 bullish TA indicator(s).

  • AXDX’s TA Score: 2 bullish, 5 bearish.
  • HBIO’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, AXDX is a better buy in the short-term than HBIO.

Price Growth

AXDX (@Medical Specialties) experienced а +1.09% price change this week, while HBIO (@Medical Specialties) price change was -16.73% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.

Reported Earning Dates

AXDX is expected to report earnings on Nov 09, 2023.

HBIO is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Medical Specialties (-4.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HBIO($184M) has a higher market cap than AXDX($19.3M). AXDX YTD gains are higher at: -52.806 vs. HBIO (-60.000). HBIO has higher annual earnings (EBITDA): 8.03M vs. AXDX (-52.74M). AXDX has more cash in the bank: 21.2M vs. HBIO (4.28M). AXDX has less debt than HBIO: AXDX (36.6M) vs HBIO (42.8M). HBIO has higher revenues than AXDX: HBIO (112M) vs AXDX (12M).
AXDXHBIOAXDX / HBIO
Capitalization19.3M184M10%
EBITDA-52.74M8.03M-656%
Gain YTD-52.806-60.00088%
P/E RatioN/AN/A-
Revenue12M112M11%
Total Cash21.2M4.28M495%
Total Debt36.6M42.8M86%
FUNDAMENTALS RATINGS
AXDX vs HBIO: Fundamental Ratings
AXDX
HBIO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10091
PRICE GROWTH RATING
1..100
4587
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXDX's Valuation (22) in the Biotechnology industry is significantly better than the same rating for HBIO (99). This means that AXDX’s stock grew significantly faster than HBIO’s over the last 12 months.

AXDX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HBIO (100). This means that AXDX’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's SMR Rating (91) in the Biotechnology industry is in the same range as AXDX (100). This means that HBIO’s stock grew similarly to AXDX’s over the last 12 months.

AXDX's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for HBIO (87). This means that AXDX’s stock grew somewhat faster than HBIO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for AXDX (100). This means that HBIO’s stock grew significantly faster than AXDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXDXHBIO
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
76%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 13 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bullish Trend 7 days ago
76%
Bearish Trend 4 days ago
84%
View a ticker or compare two or three
Ad is loading...
AXDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSHNX13.91-0.13
-0.93%
Morgan Stanley Inst Permanence A
MPSIX25.68-0.28
-1.08%
Principal MidCap S&P 400 Index Inst
PFSLX80.74-1.07
-1.31%
Paradigm Select
GCSSX29.25-0.42
-1.42%
Goldman Sachs Small Cap Eq Insghts Svc
JCONX31.35-0.64
-2.00%
Janus Henderson Contrarian I

AXDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXDX has been loosely correlated with LFTSF. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if AXDX jumps, then LFTSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXDX
1D Price
Change %
AXDX100%
-1.07%
LFTSF - AXDX
36%
Loosely correlated
N/A
MEDP - AXDX
25%
Poorly correlated
-7.23%
ME - AXDX
25%
Poorly correlated
-21.47%
HBIO - AXDX
23%
Poorly correlated
-6.55%
BLCO - AXDX
22%
Poorly correlated
+0.56%
More